Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.46 |
| ▸ | LCK | P06239 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | STK17A | Q9UEE5 | 3/20 | 0.38 |
| ▸ | STK17B | O94768 | 2/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.37 |
| ▸ | POLA1 | P09884 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30791250 | 1.00 | EGFR (0.46) | EGFRLCKLMNASTK17ASTK17B | |
| SCHEMBL23356085 | 0.79 | NLRP3 (0.37) | — | |
| SCHEMBL30791243 | 0.79 | JAK2 (0.50) | LMNASTK17ANPC1RAB9ATP53 | |
| SCHEMBL23356033 | 0.79 | JAK2 (0.50) | LMNASTK17ANPC1RAB9ATP53 | |
| SCHEMBL30791246 | 0.78 | SOS1 (0.32) | — | |
| SCHEMBL23356052 | 0.78 | SOS1 (0.32) | — | |
| SCHEMBL30791200 | 0.78 | EGFR (0.46) | EGFRHTTSMN1; SMN2 | |
| SCHEMBL23356028 | 0.78 | EGFR (0.46) | EGFRHTTSMN1; SMN2 | |
| SCHEMBL23356003 | 0.77 | EGFR (0.44) | EGFR | |
| SCHEMBL30791221 | 0.77 | EGFR (0.44) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583852-B2 | Heterocycle derivative | JW PHARMACEUTICAL CORPORATION (KR) | 2026-03-24 | — | — | US | disclosed |
| CN-112313232-B | Novel heterocyclic derivatives | JW中外制药公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20220259199-A1 | NOVEL HETEROCYCLE DERIVATIVE | JW PHARMACEUTICAL CORPORATION (KR) | 2022-08-18 | — | — | US | disclosed |
| EP-3822270-A1 | NOVEL HETEROCYCLE DERIVATIVE | JW Pharmaceutical Corporation (KR) | 2021-05-19 | — | — | EP | disclosed |
| CN-112313232-A | Novel heterocyclic derivatives | JW中外制药公司 | 2021-02-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583852-B2 | Heterocycle derivative | AR, SRD5A1, NR5A1 | EGFR 787/4885LCK 696/4885LMNA 1947/4885 |
| US-20220259199-A1 | NOVEL HETEROCYCLE DERIVATIVE | AR, BRDT, NR5A1 | EGFR 1730/4885LCK 805/4885LMNA 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.